Iranian Journal of Pharmaceutical Sciences

Vol. 20 No. 1 (2024)

First Report of Molecular Characterization of Extended Spectrum Beta-Lactamase-Producing Acinetobacter baumannii among Debilitated Patients in Tertiary Care Hospital, Ebonyi State, Nigeria Extended Spectrum β-Lactamase-Producing A. Baumannii

Iranian Journal of Pharmaceutical Sciences, Vol. 20 No. 1 (2024), 15 January 2024 , Page 41-52
https://doi.org/10.22037/ijps.v20i1.43828

Abstract

Extended Spectrum Beta Lactamase (ESBL)-Producing Acinetobacter baumannii has threatened patients’ optimal healthcare in various tertiary care hospitals globally. The paucity of information regarding this life-threatening organism in Nigeria necessitated this research. Hence, this study aimed to molecularly characterize ESBL-producing A. baumannii among debilitated patients in a tertiary care hospital in Ebonyi State, Nigeria. Debilitated patients admitted in the intensive care unit (ICU), medical, surgical, and orthopedic wards were sampled, and 385 clinical samples were obtained from them over a six-month study period. Standard microbiological methods were used to identify A. baumannii isolates, while 16S rRNA PCR was used to confirm the isolates molecularly. The Kirby-Bauer disc diffusion techniques were used to ascertain the antibiotic sensitivity profiles of A. baumannii isolates. The double disc synergy test (DDST) method was employed to determine ESBLs production among the isolates, while to determine A. baumannii isolates harboring blaTEM, blaSHV, and blaOXA genes, PCR techniques were used. A total of 23 (6%) A. baumannii isolates were recovered from 385 clinical samples. The isolated A. baumannii exhibited multidrug resistance (MDR) traits, while 43.5% of the isolates were ESBL-producing A. baumannii. Also, 9 (90%) and 3 (30%) of the isolated A. baumannii harbored blaTEM and blaOXA genes, respectively, while no isolate harbored the blaSHV gene. The isolated A. baumannii were observed to harbor ESBL genes. Importantly, this is the first report of ESBL-producing A. baumannii in Ebonyi State, Nigeria.

Keywords:
  • Acinetobacter baumannii
  • , Environmental health
  • blaSHV genes
  • Multidrug resistance

How to Cite

Egwu, I. H., Egwu-Ikechukwu, M. M., Oke, B., & Nnabugwu, C. C. (2024). First Report of Molecular Characterization of Extended Spectrum Beta-Lactamase-Producing Acinetobacter baumannii among Debilitated Patients in Tertiary Care Hospital, Ebonyi State, Nigeria: Extended Spectrum β-Lactamase-Producing A. Baumannii. Iranian Journal of Pharmaceutical Sciences, 20(1), 41–52. https://doi.org/10.22037/ijps.v20i1.43828

References

Essam JA, Mohamed AK, Rayan YB, Basel MA, Musaad AA, Fayez SB. Molecular characterization of extended‑spectrum beta‑lactamases (ESBLs) produced by clinical isolates of Acinetobacter. Ann.Clin.Microbio.lAntimicrob.(2015) 14(38): 1-9.

Asif M, Iqbal AA, Shafiq UR. Insight into Acinetobacterbaumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect. Drug. Resist.(2018)11: 1249-1260.

Iroha IR, Aniokette U, Ejikeugwu CP, Iroha CS, Aja MI, Nwakaeze AE. Occurrence of multidrug resistant Gram negative bacteria from poultry and poultry products sold in Abakaliki metropolis, Nigeria. J. Agric. Sci. Food. Sci. Technol.(2016) 2(7): 119-124.

Egwu IH, Iroha IR, Elom PC, Agwu MM, Ejikeugwu PC. Acinetobacter baumannii prevalence in federal teaching hospital, Abakaliki, Nigeria. J.Pharm. Boil.(2015)5(1): 39-43.

Dijkshoorn L, Van Aken E, Shunburne L, Van Dar Reijden TJ, Bernards AT, Nemec A. Prevalence of Acinetobacterbaumanniiand other Acinetobacterspp. In faectal samples from non hospitalized individuals. Clin.Microbiol. Infect.(2005)11: 329-332.

Zaniani FR, Meshkat Z, Nasab MN, Khaje-Karamadini M, Ghazvini K, Esmaily H.The prevalence of TEM and SHV genes among extended-spectrum beta-lactamases producing Escherichia coli and KlebsiellaPneumoniae. Iran. J. Basic Med. Sci.(2012) 15(1): 654-660.

Nassar RMA, Lafi MAK, Salman SM. The incidence of pan-drug resistance in a sample of Acinetobacterbaumanniiclinical isolates obtained from Al-Ramadi Teaching Hospital. Iraqi J. Comm. Med.(2013) 3: 262-266.

Omololu-Aso J, Oluwatoyin O, Omololu A, Egbedokun A, Olufunmilayo O, Otusanya E. Antibiotic susceptibility pattern of Escherichia coli isolated from out-patient individuals attending the university college hospital (UCH), Ibadan, Nigeria. J.Infec. Dis. Treat.(2017) 3(1): 1-4.

Henry KH. Phenotypic and molecular characterization of extended-spectrum βeta-lactamases in Klebsiella pneumonia and Escherichia coli isolates in Accra, Ghana. A thesis submitted to the University of Ghana, Legon. Department of Microbiology, School of Biomedical and Allied Health Sciences, College of Health Sciences, in partial fulfillment of the requirement for the award of Ph. D Microbiology degree. pp.1-37, 58-100: (2015).

Shamki JS, Al-Charrakh AH, Al-Khafaji JK. Detection of ESBLs in EnteropathogenicE. coli (EPEC) isolates associated with infantile diarrhoea in Kut city. Med. J. Babylon(2012) 9(2): 403-412.

Al-Hamadani AH, Al-Rikabi AM, Al- Fatlawi AF. Detection of TEM and SHV genes in Escherichia coli and Klebseilla species isolated from cancer patients in Al-Diwaniya Governorate Qatar. Med. J.(2013) 9(16): 1-5.

Fluit AC, Visser MR, Schmitz FJ. Molecular detection of antimicrobial resistance. Clin.Microbiol. Rev.(2001) 14(4): 836–871.

Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: A clinical update. Clin.Microbiol. Rev.(2005) 18(4): 657–686.

Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob. Agents and Chemother.(2010) 54(3): 969–976.

Naas T, Cuzon G, Bogaerts P, Glupczynski Y, Nordmann P. Evaluation of a DNA microarray (Check-MDR CT102) for rapid detection of TEM, SHV, and CTX-M extended-spectrum beta-lactamases and of KPC, OXA-48, VIM, IMP, and NDM-1 carbapenemases. J.Clin. Microbiol.(2011) 49(4): 1608–1613.

Naas T, Oxacelay C, Nordmann P. Identification of CTX-M-type extended-spectrum-β-lactamase genes using real-time PCR and pyrosequencing. Antimicrob. AgentsChemother.(2007)51(1): 223–230.

Ghafourian S, Sadeghifard N, Soheili S, Sekawi Z. Extended spectrum beta-lactamases: Definition, classification and epidemiology. Curr. Issues Mol. Biol.(2015) 17: 11-22.

Aarestrup FM. Meta-analysis of proportion estimates of Extended- Spectrum-Beta-Lactamase producing Enterobacteriaceaein East Africa hospitals. Antimicrob. Resist. Infect. Control(2006) 5: 18.

Egwu IH, Iroha IR, Egwu-Ikechukwu MM, Peter IU, Nnabugwu CC, Ali CM, Elom EE, Ogene LN, Edemekong CI, Mohammed ID. Antimicrobial susceptibility pattern and molecular identification of Acinetobacterbaumannii in Alex Ekwueme-Federal University Teaching Hospital Abakaliki, Nigeria. J. Pharm. Res. Int.(2021) 33(44B): 409-419.

Collee JG, Fraser AG, Marmino BP, Simons A. Practical Medical Microbiology. 14thed.USA: Mackin and McCartney: (1996).

Sepideh M, Reza M, Faramaz M. Multidrug resistance in Acinetobacterbaumannii strains isolated from clinical specimens from three hospital in Tehran- Iran. Afr. J.Microbiol. Res.(2011) 5(21): 3579 - 3982.

Azhar AL, Al- Thahab. Molecular Detection of extended- spectrum beta- lactamases in clinical isolates of Acinetobacterbaumannii. J. Boil Agric.Healthc.(2013) 3(7): 307- 311.

Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Twenty-Seventh Informational Supplement M100-S27: (2017).

Bosshard PP, Abel S, Attwegg M, Bottger EC, Zbinden R. Comparison of conventional and molecular methods for identification of aerobic catalase-negative Gram positive cocci in the clinical laboratory. J.Clin.Microbiol. (2004)42(5): 2065-2073.

Raible KM, Bhaswati S, Law1 N, Tiffany EB, Christopher LE, Garth DE. Molecular characterization of β‑lactamase genes in clinical isolates of carbapenem‑resistant Acinetobacterbaumannii. Ann.Clin.Microbiol.Antimicrob.(2017)16(75): 1-10.

Peleg AY, Seifert H, Paterson DL. Acinetobacterbaumannii: emergence of a successful pathogen. Clin.Microbiol. Rev.(2008) 21(3): 538–82.

Odewale G, Adefioye1 OJ, Ojo J, Adewumi FA, Olowe OA. Multidrug resistance of Acinetobacterbaumanniiin LadokeAkintola University Teaching Hospital, Osogbo, Nigeria. Eur. J.Microbiol.Immunol.(2016) 6(3): 238–243.

[28] Rit K, Saha R. Multidrug-resistant Acinetobacter infection and their susceptibility patterns in a tertiary care hospital. Nigerian Medical Journal(2012)53: 126–128.

[29] Nwadike VU, Fayemiwo SA, Fowotade A, Bakare RA, Olusanya O. Nosocomial Acinetobacterin a tertiary facility. J. Infect. Dis.(2012)8(4): 181-186.

[30] Mostofi S, Mirnejad R, Masjedian F. Multidrug resistance in Acinetobacterbaumannii strains isolated from clinical specimens from three hospitals in Tehran-Iran. Afri. J.Microbiol. Res.(2011)5: 3579–3582.

[31] Joshi SG, Litake GM, Satpute MG, Telang NV, Ghole VS, Niphadkar KB. Clinical and demographic features of infection caused by Acinetobacter Species. Indian J. Med. Sci.(2006)60: 351–360.

[32] Dash M, Padhi S, Swetlana P, Indrani M, Pooja, M. Frequency, risk factors, and antibiogram of Acinetobacter species isolated from various clinical samples in a tertiary care hospital in Odisha. Avicenna J. Med.(2013)3(4):97–102.

[33] Parviz M, Abbas F, Mohammad MF, Hosnieh K, Ramin A, Farid N. Antimicrobial susceptibility profiling and genomic diversity of Acinetobacter baumannii isolates: A study in western. Iran. J. Microbiol.(2013) 5(3): 95-202.

[34] Al-Hasnawy HH, Rasha HS, Bara´ Hamid H.Existence of ESBL genes in Escherichia coli and Acinetobacter baumanniiisolated from different clinical specimens. J. Pharm. Sci. Res.(2018) 10(5): 1112-1117.

  • Abstract Viewed: 465 times
  • IJPS_Volume20_Issue1_Pages41-52 Downloaded: 71 times

Download Statastics

Developed By

Open Journal Systems

Information